Adrian Dörig

• "Adrian Dörig handles acquisition and corporate finance for clients from the biopharmaceutical and technology industries. Clients report him to be "very diligent."
• "Adrian Dörig stands out for his work on direct lending transactions on behalf of international investment funds. Sources appreciate that he "understands the market and can tailor his advice to the type of transaction and the people involved."
• "Adrian Dörig is valued by one commentator for his 'sharp analytical mind' as well as being 'strong in articulating and advocating our position in finance matters.'
• "Interviewees describe Adrian Dörig as a 'very good negotiator who also understands the client's desire to control costs. 'He focuses on structured finance transactions and has expert knowledge of aircraft finance.'

Adrian Dörig heads the banking and finance practice team at VISCHER. He specialises in structured finance transactions, in particular acquisition, restructuring and lease financing. Aviation finance is a stronghold. He also deals with regulatory and contractual issues relating to financial services, collective investment schemes and asset management. In addition, he advises clients on M&A projects and real estate transactions.

• Advised Urovant Sciences (Nasdaq: UROV), in the USD 100 million debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) and in the USD 300 million term loan facility with Sumitomo Dainippon Pharma Co., Ltd.
• Advised the target BFW Liegenschaften AG with respect to the public tender offer by BFW Holding AG (going private transaction), the advice also addressing important corporate finance aspects of the offer.
• Advised AFINUM, one of the leading mid-cap investment firms in the German-speaking region, in its acquisition of a majority stake in the Swiss Interconnect Group.
• Advised Bregal Unternehmerkapital, currently managing around EUR 2.5 billion in overall assets, on the establishment of a strategic alliance between Embassy Jewel AG (controlled by Bregal Unternehmerkapital) and the Kirchhofer Group (family-owned) to become one of the two leading watch and jewellery retailers in Switzerland.
• Advised Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders, in a USD 180 million financing to acquire the exclusive rights from Korean SK Biopharmaceuticals to develop and commercialise cenobamate in Europe supported by a global syndicate of investors led by LSP and including NovaQuest, BRV Capital Management, Andera Partners, and H.I.G. BioHealth Partners.

• Banking
• Financial restructuring
• M&A
• Private equity
• Structured finance/securitisation

• Aviation
• Financial services
• Pharma and life sciences
• Real estate
• Tech and telecoms

• Zurich Bar Association
• Swiss Bar Association
• International Bar Association
• Member of the Advisory Board Forum Kapitalmarktinstrumente - Kapitalmarktfinanzierung e.V.

• University of St. Gallen, HSG (Dr. iur., 1998)
• University of Virginia (LL.M., 1996)
• University of St. Gallen, HSG (lic. iur., 1992)